ABT-199: taking dead aim at BCL-2

Matthew S Davids; Anthony Letai

doi:10.1016/j.ccr.2013.01.018

ABT-199: taking dead aim at BCL-2

Cancer Cell. 2013 Feb 11;23(2):139-41. doi: 10.1016/j.ccr.2013.01.018.

Authors

Matthew S Davids¹, Anthony Letai

Affiliation

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.

Abstract

ABT-199 is a new selective small molecule inhibitor of BCL-2 that appears to spare platelets while achieving potent antitumor activity. Assays that can predict the efficacy of ABT-199 in individual tumors will be critical in determining how best to incorporate this promising agent into the armamentarium of cancer therapies.

Publication types

Research Support, Non-U.S. Gov't

Abstract

Publication types

Grants and funding